相关实验视频
Updated: Jun 17, 2025

05:34
5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
Published on: April 4, 2025
530
在多种有效治疗的时代,优化脏和心血管保护
1Centre for Kidney Research and Innovation, Academic Unit for Translational Medical Sciences, School of Medicine, University of Nottingham, Nottingham.
Current opinion in nephrology and hypertension
|August 13, 2024
概括
新的治疗方法,如糖携运输体2抑制剂,在减缓慢性病 (CKD) 进展和减少心血管事件方面具有显著的益处. 组合疗法显示出有希望的结果,但需要进一步的研究和服务调整以获得有效的患者护理.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 心脏病学 心脏病学
- 内分泌学 在内分泌学.
背景情况:
- 慢性病 (CKD) 管理历史上依赖于高血压控制和氨酸-血管酶系统抑制剂.
- 随着多种有效的治疗方案的出现,出现了一个范式的转变,以减缓CKD进展.
研究的目的:
- 审查新型CKD治疗的机制和益处.
- 讨论实现CKD最佳组合疗法的挑战.
主要方法:
- 过去5年发表的大型临床试验的综述.
- 在CKD中分析了糖共运输体2抑制剂,非类固醇矿物质皮质激素抗剂和葡萄糖类-1受体激动剂的证据.
主要成果:
- 糖共传输体2抑制剂显著降低CKD进展和心血管事件在不同的CKD群体.
- 非类固醇矿物质皮质类固醇抗剂和类似葡萄糖-1受体激动剂在2型糖尿病和CKD患者中显示有好处.
- 新型疗法的机制表明,在组合中具有附加性益处,尽管直接证据有限.
结论:
- 需要进一步的临床试验来验证结合疗法在CKD中的益处.
- 实施最佳组合疗法需要服务重组,患者教育和监测.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
405
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
405
Heart Failure Drugs: Diuretics
352
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
352
Antihypertensive Drugs: Potassium-Sparing Diuretics
482
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
482
Antihypertensive Drugs: Direct Renin Inhibitors
513
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
513
Hypertension and Regulation of Blood Pressure
2.0K
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
2.0K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
541
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
541

